ClinicalTrials.gg
RecruitingNCT07341282DRIVE-UPUpdated Oct 9, 2026

Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis

A Phase 2 interventional study of Placebo (blinded) and Vancomycin (blinded) in Ulcerative Colitis (UC) and Primary Sclerosing Cholangitis (PSC), sponsored by McMaster University. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by McMaster University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 9, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 265 studies in Colitis, Ulcerative with a site in Canada — 47 open to participants now, 84 under way, 24 of them phase 3. Colitis, Ulcerative · Canada.

Planned enrollment
219th of 227
14 · median 162
Started
2026
with 15 others
Phase 2
74 of 265
13 open now
Primary completion
2027-12
later than 54 of 83 live
Registered
254th of 265
by date

Among the 265 studies in Colitis, Ulcerative with a site in Canada, this one is the 219th largest by planned enrollment of the 227 interventional ones that give a count, is one of 16 that started in 2026, is one of 74 in phase 2, reaches primary completion later than 54 of the 83 other live ones, and was the 254th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

47 of the 265 studies in Colitis, Ulcerative with a site in Canada are open now. Recruiting first, the newest first:

41 more — sign in →

All 47 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Colitis, Ulcerative with a site in Canada, or all of them as a file.
02

Study summary

This clinical trial tests if oral vancomycin can safely treat active ulcerative colitis (UC) in adults who also have primary sclerosing cholangitis (PSC), a liver condition. The main questions it aims to answer are:

  • Can oral vancomycin improve UC symptoms as measured by Mayo score at 4 weeks?
  • Is oral vancomycin safe and tolerable in this patient group?

Participants will be compared to see if vancomycin works better than placebo. Participants will:

  • Take oral vancomycin (250 mg twice daily) or identical placebo capsules for 4 weeks
  • Have the option for 4 more weeks of open-label vancomycin after the blinded phase
  • Attend clinic visits at baseline, week 4, and follow-up for Mayo scoring, endoscopy, blood/stool tests, and safety checks
  • Track treatment adherence and side effects

The study primarily assesses if the trial can recruit 14 participants, retain them, achieve good adherence, and follow protocol procedures (feasibility). Secondary goals include safety (adverse events) and early signs of benefit in UC activity, liver tests, and gut bacteria balance. This pilot will guide larger future studies.

Read the detailed description

This is an investigator-initiated feasibility study designed to rigorously characterize clinical response signals, safety parameters, and feasibility metrics in adults with co-existing PSC and UC, a population where microbiome-targeted immune modulation is hypothesized to influence disease activity.

Randomization \& Allocation Governance

  • Randomization will be implemented using validated computer-generated randomization software, with the allocation sequence generated by a study statistician not involved in clinical assessments.
  • Allocation concealment will be maintained through centralized pharmacy control. An independent pharmacist will assign treatment codes and release sequentially numbered study medication containers.
  • Blinding integrity will be preserved through visual and packaging equivalence, sequential drug accountability logs, and restricted access to treatment codes until database lock.
  • Emergency unblinding is permitted only when required for clinical management, and all unblinding events will be documented, timestamped, and reviewed by the DSMC.

Clinical Visit \& Assessment Schedule

Participants will complete a structured study visit pathway:

  • Screening (≤14 days before baseline): medical history review, infection risk screening, liver disease stability assessment, and confirmation of clinical trial eligibility documentation.
  • Baseline (Week 0): clinical evaluation, safety labs, medication reconciliation, and flexible sigmoidoscopy performed by credentialed endoscopists using a standardized endoscopic scoring handbook.
  • Week 2 \& 4: in-clinic evaluation, adverse event review, safety labs, and compliance verification via pill count and participant diary reconciliation.
  • Week 8 (extension follow-up): final safety labs, medication reconciliation, delayed adverse event capture, and optional qualitative feasibility interview.

Adherence \& Safety Surveillance

  • Participants will complete weekly digital symptom and adherence diaries capturing stool frequency, rectal bleeding trends, abdominal pain patterns, and missed doses.
  • Safety labs include CBC, creatinine, liver panel, CRP, albumin, electrolytes, and will be evaluated at baseline, week 2, 4, and 8.
  • A hepatologist co-investigator will review liver safety signals in real-time, given PSC-specific vulnerability to hepatic decompensation.
  • Audiology risk is screened at entry, and any symptoms concerning for ototoxicity will prompt same-week clinical review.

Data Capture \& Monitoring Integrity

  • All data will be captured in a secure Excel file
  • Endoscopic images will be stored in a secured institutional imaging server.
  • A pre-registered statistical analysis plan will be finalized before unblinding, with analysis scripts locked prior to treatment code release.

Safety Governance Structure

The DSMC will provide independent oversight and safety adjudication:

  • Quarterly DSMC meetings will evaluate cumulative safety logs, recruitment feasibility, protocol deviations, and unblinding reports.
  • A real-time SAE notification system ensures DSMC alert within 24 hours of serious adverse event reporting.
  • Pre-defined individual, arm-level, and whole-trial safety review thresholds are codified in the DSMC governance charter to support early pause or protocol modification when required.

Regulatory \& Ethical Compliance

The trial will follow all institutional and international regulatory standards:

  • ICH-GCP
  • Institutional Research Ethics Board approval
  • DSMC governance charter
  • GMP-aligned pharmacy accountability procedures
03

Conditions studied

  • Ulcerative Colitis (UC)
  • Primary Sclerosing Cholangitis (PSC)

Keywords

  • Ulcerative Colitis
  • Primary Sclerosing Cholangitis
  • Vancomycin
  • Randomized Control Trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  • Adults aged ≥18 years.
  • Confirmed diagnosis of UC and PSC.
  • Moderate to severe UC disease activity (total Mayo score ≥5; endoscopic subscore ≥2).
  • provided. Exclusion Criteria
  • Diagnosis of Crohn's disease or indeterminate colitis.
  • Fulminant colitis or need for immediate surgical intervention.
  • Use of antibiotics or probiotics within the past 4 weeks (for microbiome substudy).
  • Decompensated liver disease ( B/C).
  • Severe Renal Impairment ( \<30mL/min)
  • Active untreated infection.
  • Pregnancy or lactation.
  • Prior allergy or intolerance to Vancomycin
  • History of hearing loss or current hearing problems
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Comparator

    4 weeks blinded placebo followed by optional 4 weeks open-label vancomycin.

    Drug: Placebo (blinded) · Drug: Vancomycin (open-label extension)

  • Experimental
    Vancomycin

    4 weeks blinded oral vancomycin followed by optional additional 4 weeks open-label vancomycin.

    Drug: Vancomycin (blinded) · Drug: Vancomycin (open-label extension)

Interventions

  • DrugPlacebo (blinded)

    Identical placebo capsule administered orally twice daily for 4 weeks.

  • DrugVancomycinStudies of VancomycinVancomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Vancomycin 250 mg administered orally twice daily for 4 weeks.

  • DrugVancomycinStudies of VancomycinVancomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Vancomycin 250 mg administered orally twice daily for 4 weeks (optional extension offered to both arms).

06

What researchers measure

Primary outcomes

  1. Recruitment rate

    Proportion of eligible participants who provide consent and are enrolled in the study (number enrolled ÷ number eligible approached), with a target of 14 participants within 12 months.

    Time frame: 12 months

  2. Retention rate

    Proportion of enrolled participants who complete all protocol-specified study visits and assessments at 12 months (number completing all follow-up visits ÷ number enrolled).

    Time frame: 12 months

  3. Treatment adherence

    Proportion of prescribed oral vancomycin doses taken over the treatment period, assessed by pill counts and/or medication diary (number of doses taken ÷ number of doses prescribed).

    Time frame: 12 months

  4. Protocol compliance with study procedures

    Proportion of participants with all required visits, laboratory tests, and assessments completed per protocol (number fully compliant ÷ number enrolled); may also include rate of major protocol deviations.

    Time frame: 12 months

Secondary outcomes

  1. Incidence of adverse events and serious adverse events

    Proportion of participants with at least one treatment-emergent adverse event (AE) or serious adverse event (SAE)

    Time frame: 12 months

  2. Severity and type of adverse events

    Number of treatment-emergent AEs and SAEs by maximum severity grade (mild/moderate/severe) and type (MedDRA preferred term).

    Time frame: 12 months

  3. Relationship of adverse events to oral vancomycin

    Proportion of AEs/SAEs assessed by investigator as related to intervention (number related ÷ total events).

    Time frame: 12 months

  4. Patient-reported tolerability of oral vancomycin

    Mean score of side effect frequency and impact on 0-10 scale (0=no impact, 10=worst impact) via study questionnaire.

    Time frame: 12 months

Other outcomes

  1. Exploratory Endpoints (Change in Mayo Score from baseline)

    Change in partial Mayo Clinic Score (range 0-12 points, higher scores indicate greater ulcerative colitis disease activity) from baseline to 12 months.

    Time frame: 12 months

  2. Exploratory Endpoints (Change in serum liver enzymes from baseline)

    Change in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels (units: U/L) from baseline to 12 months.

    Time frame: 12 months

  3. Exploratory Endpoints (Change in gut microbiome diversity from baseline)

    Change in gut microbiome diversity (Shannon index, unitless) measured by 16S rRNA sequencing of fecal samples from baseline to 12 months.

    Time frame: 12 months

  4. Exploratory Endpoints (Change in fecal bile acids from baseline)

    Change in total fecal bile acid concentration (units: μmol/g) measured by mass spectrometry from baseline to 12 months.

    Time frame: 12 months

  5. Exploratory Endpoints (Change in fecal short chain fatty acids from baseline)

    Change in total fecal short chain fatty acid concentration (units: μmol/g), including acetate, propionate, and butyrate, measured by gas chromatography from baseline to 12 months.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • McMaster Children's Hospital - Digestive Diseases Clinic
    Hamilton, Ontario L8N 3Z5, Canada
    Recruiting
08

References and documents

Publications

  • Arbabzada N, Dennett L, Meng G, Peerani F. The Effectiveness of Oral Vancomycin on Inflammatory Bowel Disease in Patients With Primary Sclerosing Cholangitis: A Systematic Review. Inflamm Bowel Dis. 2025 Jul 7;31(7):2027-2035. doi: 10.1093/ibd/izae257. PubMed 39495039 ↗
  • Shah A, Macdonald GA, Morrison M, Holtmann G. Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework. Am J Gastroenterol. 2020 Jun;115(6):814-822. doi: 10.14309/ajg.0000000000000604. PubMed 32250997 ↗
  • Al Sulais E, AlAmeel T, Alenzi M, Shehab M, AlMutairdi A, Al-Bawardy B. Colorectal Neoplasia in Inflammatory Bowel Disease. Cancers (Basel). 2025 Feb 16;17(4):665. doi: 10.3390/cancers17040665. PubMed 40002259 ↗
  • Castano-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014 Apr;39(7):645-59. doi: 10.1111/apt.12651. PubMed 24612141 ↗
  • Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013 Mar-Apr;19(4):789-99. doi: 10.1097/MIB.0b013e31828029c0. PubMed 23448792 ↗
  • Lundberg Bave A, Bergquist A, Bottai M, Warnqvist A, von Seth E, Nordenvall C. Increased risk of cancer in patients with primary sclerosing cholangitis. Hepatol Int. 2021 Oct;15(5):1174-1182. doi: 10.1007/s12072-021-10214-6. Epub 2021 Aug 6. PubMed 34357546 ↗
  • Risques RA, Lai LA, Himmetoglu C, Ebaee A, Li L, Feng Z, Bronner MP, Al-Lahham B, Kowdley KV, Lindor KD, Rabinovitch PS, Brentnall TA. Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res. 2011 Mar 1;71(5):1669-79. doi: 10.1158/0008-5472.CAN-10-1966. PubMed 21363920 ↗
  • Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011 May;140(6):1807-16. doi: 10.1053/j.gastro.2011.01.057. PubMed 21530747 ↗
  • Uzdzicki AW, Wawrzynowicz-Syczewska M. Characteristic features of ulcerative colitis with concomitant primary sclerosing cholangitis. Prz Gastroenterol. 2021;16(3):184-187. doi: 10.5114/pg.2021.108983. Epub 2021 Sep 17. PubMed 34584578 ↗

Individual participant data

Plan to share: Yes — Data sharing policies would follow institutional and regulatory standards on data confidentiality and sharing. De-identified data shared upon request to qualified researchers with appropriate data use agreements, respecting participant confidentiality and ethical approvals. Patient demographics, primary data and data analysis can be shared.

Supporting information: Study protocol

Time frame: Start Date is estimated in January 2026 - end date is estimated in December 2026.

Access criteria: Access to IPD and supporting study documents will generally limited to qualified researchers who submit a reasonable scientific request and have the necessary expertise. The data shared would be de-identified or anonymized to protect participant confidentiality. Researchers might be granted access under data use agreements that specify the terms of use, including restrictions on re-identification and further sharing. Access is often facilitated through secure data repositories or by request through the trial sponsor or coordinating research unit after review and approval of the request.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 45 non-industry phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's planned 18 months is below that.

Counting every sponsor, half of 155 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Jan 2026 → Jun 2026, primary completion Dec 2026 → Dec 2027 and completion Mar 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Jan 14, 2026
StartActual
Jun 17, 2026was Jan 2026
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Dec 2027was Mar 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
McMaster Children's Hospital - Digestive Diseases Clinic is now Recruiting
Oct 9, 2026
Start date
Jan 2026→Jun 17, 2026 (actual)
Oct 9, 2026
Primary completion
Dec 2026→Dec 2027
Oct 9, 2026
Study completion
Mar 2027→Dec 2027
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    McMaster Children's Hospital - Digestive Diseases Clinic is now Recruiting
    Start date Jan 2026→Jun 17, 2026 (now actual)
    Primary completion Dec 2026→Dec 2027
    Study completion Mar 2027→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07341282
Collaborators
Weston Family Foundation
Responsible party
Sponsor
First posted
Jan 14, 2026
Start date
Jun 17, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Neeraj Narula, MD
Contact
neeraj.narula@medportal.ca
905-521-2100 ext. 73884
Jaimin Patel
Contact
patej102@mcmaster.ca
905-521-2100 ext. 73884
Neeraj Narula, MD
principal investigator · McMaster University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vancomycin

Start the discussion